Factor VIII gene therapy - Chiron/INEX

Drug Profile

Factor VIII gene therapy - Chiron/INEX

Latest Information Update: 16 Dec 1998

Price : $50

At a glance

  • Originator Chiron Corporation; Inex Pharmaceuticals Corporation
  • Class Blood coagulation factors; Coagulants
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia

Most Recent Events

  • 16 Dec 1998 Discontinued-Preclinical for Haemophilia in Canada (Unknown route)
  • 16 Dec 1998 Discontinued-Preclinical for Haemophilia in USA (Unknown route)
  • 28 Oct 1997 Preclinical development for Haemophilia in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top